BIOPHARMA
By
VA’s Nationwide Ambient AI Scribe Rollout: Burnout Buster or Documentation Digitized Trap?
The U.S. Department of Veterans Affairs on March 4, 2026, greenlit ambient scribe AI from Knowtex and Abridge…
Gilead’s $8B Arcellx CAR-T Swoop & Lilly Zepbound Triumph: Obesity/CAR-T Mania or Bubble Burst Ahead?
Gilead’s March 2026 $8B acquisition of Arcellx—securing CAR-T anito-cel for multiple myeloma with 73% ORR Phase 1b data—and…
FDA’s AZ/GSK Biologics Rejections: Data Integrity Wake-Up or R&D Overhaul Catalyst?
FDA rejection letters issued March 3-4, 2026, flagged data integrity lapses in AstraZeneca’s subcutaneous tezepelumab (asthma) and GSK’s…
Acadia’s Daybue CHMP Fight: $2B Rett Revenue at Stake or EMA Brick Wall?
Acadia Pharmaceuticals on March 3, 2026, fired back at CHMP’s rejection of Daybue (trofinetide) expansion into granular symptom…
How Does Novo Nordisk Transform Metabolic Leadership Into Multi-Billion Dollar Dominance Through 2030?
Novo Nordisk executes a “multi-mechanism obesity fortress” strategy under new CEO Mike Doustdar, reallocating R&D firepower from discontinued cell therapies…
How Does AstraZeneca Transform ADC Dominance Into an $80 Billion Revenue Juggernaut by 2030?
AstraZeneca masterminds an “oncology everywhere” empire through surgical deployment of 20+ late-stage novel molecular entities across oncology (43% revenue), CVRM,…
